Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 13/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.57 |
| ▸ | PDE4A | P27815 | 4/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Senazodan SCHEMBL4519202 | 0.98 | KCNH2 (0.97) | KCNH2PDE3BPDE3APDE4APDE4B | |
| Senazodan SCHEMBL1649599 | 0.98 | KCNH2 (0.97) | KCNH2PDE3BPDE3APDE4APDE4B | |
| Senazodan SCHEMBL4526209 | 0.97 | KCNH2 (0.94) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL7263634 | 0.85 | KCNH2 (0.73) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL10548193 | 0.84 | KCNH2 (0.71) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL7264027 | 0.82 | KCNH2 (0.70) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL10353452 | 0.82 | SMN1; SMN2 (0.81) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL10474131 | 0.81 | KCNH2 (0.67) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL22910067 | 0.80 | KCNH2 (0.66) | KCNH2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2478615 | 0.80 | KCNH2 (0.66) | KCNH2PDE3BPDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062295-A1 | Pharmaceutical Products | MITSUBISHI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | claimed |
| EP-1864664-A1 | PHARMACEUTICAL PREPARATION | Mitsubishi Pharma Corporation (JP) | 2007-12-12 | — | — | EP | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| US-4971968-A | CARDIOVASCULAR DISORDERS, STIMULANTS | MITSUBISHI KASEI CORPORATION (JP) | 1990-11-20 | — | — | US | claimed |
| EP-0145019-A2 | Pyridazinone derivatives and salts thereof | MITSUBISHI KASEI CORPORATION (JP) | 1985-06-19 | — | — | EP | claimed |
| JP-60126282-A | — | — | None | — | — | JP | disclosed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240207279-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| US-20040063710-A1 | Ophthalmological preparations | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1400520-A1 | CRYSTAL OF 6- 4-(4-PYRIDYLAMINO)PHENYL]-4, 5-DIHYDRO-3(2H)-PYRIDAZINONE HYDROCHLORIDE TRIHYDRATE | Mitsubishi Pharma Corporation (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1346728-A1 | OPHTHALMOLOGICAL PREPARATIONS | Mitsubishi Pharma Corporation (JP) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002088109-A1 | CRYSTAL OF 6-[4-(4-PYRIDYLAMINO)PHENYL]-4, 5-DIHYDRO-3(2H)-PYRIDAZINONE HYDROCHLORIDE TRIHYDRATE | MITSUBISHI PHARMA CORPORATION (JP) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088109-A1 | CRYSTAL OF 6-[4-(4-PYRIDYLAMINO)PHENYL]-4, 5-DIHYDRO-3(2H)-PYRIDAZINONE HYDROCHLORIDE TRIHYDRATE | MITSUBISHI PHARMA CORPORATION (JP) | 2002-11-07 | — | — | WO | disclosed |
| US-4971968-A | CARDIOVASCULAR DISORDERS, STIMULANTS | MITSUBISHI KASEI CORPORATION (JP) | 1990-11-20 | — | — | US | disclosed |
| JP-S60126282-A | PYRIDAZINONE DERIVATIVE OF SALT THEREOF | MITSUBISHI CHEM IND LTD | 1985-07-05 | — | — | JP | disclosed |
| EP-0145019-A2 | Pyridazinone derivatives and salts thereof | MITSUBISHI KASEI CORPORATION (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | KCNH2 296/4885PDE3B 84/4885PDE3A 81/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | KCNH2 296/4885PDE3B 84/4885PDE3A 81/4885 |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | KCNH2 3836/4885PDE3B 1086/4885PDE3A 638/4885 |
| US-20090062295-A1 | Pharmaceutical Products | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DPP4, CYP2D6 | KCNH2 768/4885PDE3B 207/4885PDE3A 130/4885 |
| US-20040063710-A1 | Ophthalmological preparations | EYA3, AQP4, AQP3 | KCNH2 52/4885PDE3B 406/4885PDE3A 117/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | KCNH2 3836/4885PDE3B 1086/4885PDE3A 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.